What dose of Uzedy (long‑acting injectable risperidone) is appropriate for a patient taking 4 mg oral risperidone?

Dosage Conversion from Oral Risperidone to Uzedy

For a patient taking 4 mg oral risperidone daily, the appropriate Uzedy dose is 100 mg once monthly OR 200 mg once every 2 months, administered subcutaneously. 1

Direct Conversion Guidelines

According to the FDA-approved prescribing information for Uzedy, the conversion is straightforward 1:

• 4 mg oral risperidone daily = 100 mg Uzedy once monthly
• 4 mg oral risperidone daily = 200 mg Uzedy once every 2 months

Key Administration Requirements

Critical: Uzedy must be administered by a healthcare professional as a subcutaneous injection in the abdomen or upper arm—never by any other route. 1

Timing of first injection: Administer Uzedy the day after the last dose of oral risperidone. No loading dose or oral supplementation is needed when switching. 1

Choosing Between Monthly vs. Every 2 Months Dosing

Both dosing intervals are FDA-approved for schizophrenia and provide equivalent therapeutic coverage 1:

• Once monthly (100 mg): May be preferred initially to allow more frequent dose adjustments if needed
• Once every 2 months (200 mg): Offers greater convenience and fewer injections, which may improve long-term adherence 2

Patients can switch between these two regimens by administering the first dose of the new schedule on the next scheduled date of the original regimen. 1

Important Clinical Considerations

Tolerability Confirmation

Before initiating Uzedy, establish tolerability with oral risperidone. This is an FDA requirement for patients who have never taken risperidone. 1 Since your patient is already on 4 mg oral risperidone, this requirement is satisfied.

Dosing Adjustments for Special Populations

Renal or hepatic impairment: Prior to Uzedy initiation, titrate oral risperidone to at least 2 mg daily. Following oral titration, the recommended Uzedy dose is 50 mg once monthly (not the standard 100 mg conversion). 1

Drug Interactions Requiring Dose Modification

Strong CYP2D6 inhibitors (fluoxetine, paroxetine): If initiating these medications, place the patient on a lower Uzedy dose beforehand to compensate for expected increases in risperidone plasma concentrations. For patients already on 100 mg monthly or 200 mg every 2 months, continue these doses unless clinical judgment necessitates interruption. 1

Strong CYP3A4 inducers (carbamazepine): Monitor closely during the first 4-8 weeks after initiating the inducer, as Uzedy dose increases or additional oral risperidone may be needed. 1

Advantages of This Conversion

Research demonstrates that long-acting injectable risperidone formulations provide:

• Improved adherence compared to oral medications 2, 3
• More stable plasma concentrations with reduced peak-to-trough fluctuations 4
• Maintained therapeutic D2 receptor occupancy throughout the dosing interval 5
• Reduced hospitalizations (74-80% reduction in stable patients) 6

The subcutaneous Uzedy formulation specifically achieves therapeutic exposure within hours of administration without requiring oral supplementation, unlike older intramuscular formulations. 7

Common Pitfalls to Avoid

1. Do not administer intramuscularly—Uzedy is subcutaneous only 1
2. Do not provide oral supplementation when initiating Uzedy from oral risperidone 1
3. Do not use loading doses—the conversion table provides the complete therapeutic dose 1
4. Do not assume equivalence with older risperidone LAI formulations—Uzedy has different pharmacokinetics and does not require the 3-week oral overlap needed with biweekly intramuscular risperidone 1, 8